Successful treatment pure red cell aplasia after ABO major mismatched allogeneic hematopoietic stem cell transplantation with avatrombopag and low dose rituximab.
Junjie CaoShaoyan LuDanjie LuoRenzhi PeiYing LuDong ChenXiaohong DuShuangyue LiPublished in: Transfusion (2024)
Low-dose rituximab and avatrombopag may be an effective treatment for patients with PRCA after major ABO-incompatible allo-HSCT. The patients should be treated at least 90 days post transplantation if conventional erythropoietin therapy fails.
Keyphrases
- low dose
- allogeneic hematopoietic stem cell transplantation
- diffuse large b cell lymphoma
- newly diagnosed
- end stage renal disease
- high dose
- cell therapy
- acute lymphoblastic leukemia
- acute myeloid leukemia
- ejection fraction
- chronic kidney disease
- single cell
- stem cells
- chronic lymphocytic leukemia
- mesenchymal stem cells
- patient reported